Hubert Czerniak - NIACYNA cz. 4 z 4 / Na jakie schorzenia brać witaminę B3? Sprawdź jej skuteczność!

Hubert Czerniak opens with a striking observation: patients who still bleed from gums while brushing, despite consistent vitamin C supplementation, stop bleeding when given niacin. This led to Prof. Altschul’s experiments on rabbits with diet‑induced atherosclerosis; the niacin‑treated group showed dramatic plaque regression. When the same approach was tried on humans, the results were ‘phenomenal’. Czerniak laments that modern ethics‑committee bureaucracy now hinders such direct physician‑led applications. The protocol today would require informed consent and formal trials, but the historical data support using niacin in dentistry and preventive cardiology.

Czerniak details the work of the Grunt team (‘doktor Grunt’ at the ‘Mario clinic’), who found the 22%/52% reduction figures and declared niacin unique among known agents. He juxtaposes this with the mortality caution from Uchima, Lida, and Kucharz: below 160 mg%, vascular deaths rise. This creates a therapeutic window — lower elevated lipids but do not overshoot. He criticises the present regulatory environment that, unlike the era of Altschul, would require lengthy ethics reviews to replicate such straightforward clinical observations, implying that patients are being deprived of a safe, effective treatment.

Czerniak discusses Jacobs and Kirkland’s methylation work to justify that every chemo/radiotherapy patient ‘should receive niacin’. He contrasts the mainstream focus on destroying tumour cells with the neglect of host DNA defence. He notes that human cells pre‑treated with high niacin and then exposed to a carcinogen developed cancer 90% more slowly. The implication is that niacin creates a repair‑competent environment that mitigates iatrogenic damage. The speaker references a Linus Pauling report on niacin and cancer for the interested reader.

Czerniak extensively covers the history: Kaneko cured MS in mice by elevating NAD; Hoffer replicated remission in over 60 human patients with 3–6 grams/day; Klenner published a detailed combination therapy; Guimond theorised that many neurological diseases result from cells being ‘disconnected’ from nutrients by blocked transmembrane channels. The speaker adds that metals (thimerosal, heavy metals) may be the blockers, and DMSO can act as a solvent. He references Prof. Kozłowski’s textbook for vitamin D3 dosing and emphasises that D3 must always be paired with K2 (1,000 IU D3 : 10 µg K2) and the full ADEK complex. The protocol is framed as a rational reconstruction of historical success, challenging the ‘incurable’ label of MS.

Czerniak frames this protocol against the backdrop of cost and scarcity: transplant costs $100,000 and dialysis $50,000/year, while niacin is cheap. He cites Prof. Kokot, from whose nephrology textbooks he learned, who remarked that membranous nephritis was unknown before a certain time — implying a modern dietary or toxic aetiology. The 3‑gram dose reportedly allowed patients to remain off dialysis. Although no trial specifics are given, the speaker treats this as a practical, low‑risk option that cost‑conscious systems should explore.

Czerniak recounts Nobel laureate George Wald’s work on vitamin‑A, which incidentally showed that rats deprived of B vitamins became hyperactive runners — a behaviour that niacin suppressed. Dr. William Kaufman then applied niacin therapy to reduce pathological hunger/overactivity in patients. The speaker concludes that our Western diet, rich in refined carbohydrates that lack B vitamins, is triggering this innate response, and that adequate niacin repletion is a key step in taming obesity. This reframes obesity as a nutrient‑deficiency disease rather than pure caloric sloth.

Czerniak describes how L‑dopa, the mainstay of Parkinson’s therapy, oxidises into dopamine‑chrome, a neuron‑toxic compound. Hoffer and Foster theorised that oxidation of catecholamines (dopamine, adrenaline) drives multiple neurodegenerative diseases. They advocated large‑dose antioxidants plus niacin as a methyl‑sink to handle the oxidative load. Czerniak cites that NADH given directly works as well as L‑dopa, offering a potential alternative or complementary route. He references Oliver Sacks’s ‘Awakenings’ as a dramatic illustration of L‑dopa’s power and perils, implying that the Hoffer‑Foster add‑on might sustain the benefit while reducing side effects.

Czerniak stresses that niacin, while effective for lipid control, must be used with awareness of this cut-off. He frames it as an evolutionary or physiological floor: cholesterol is essential for cell membranes, steroid hormones, and brain function, so depleting it beyond a point triggers systemic fragility. He does not advocate stopping niacin but advises monitoring, especially in patients who might be over‑treated. The finding challenges the widespread ‘cholesterol inertia’ and encourages practitioners to treat lipid numbers contextually rather than pursuing zero‑risk values.

Czerniak describes a cascade: niacin is converted to NAD, the substrate for poly‑ADP‑ribose polymerase (PARP), which detects DNA breaks and orchestrates repair. Methylation, which silences tumour‑suppressor genes, can be intercepted because niacin is one of the few natural methyl‑group acceptors, thus preventing hypermethylation. He argues that oncologists ignore these protective mechanisms, leading to unnecessary DNA damage and secondary cancers. The recommendation is broad: give niacin before, during, and after cytotoxic treatments, alongside antioxidants. He references a Linus Pauling report on niacin and cancer for deeper evidence.

While the pathophysiology is not deeply explored in the talk, Czerniak links the effect to niacin’s action on mucosal barriers, similar to its benefit on gum bleeding and endothelium. He implies that the vitamin’s anti‑secretory or barrier‑tightening property may be the mechanism, and he notes the same approach helps in other secretory diarrhoeas — pancreatic cancer and E. coli enteritis. This positions niacin as a broad‑spectrum intestinal stabiliser outside its known lipid and vascular roles.

Czerniak explains that MS involves demyelination—the nerve fibre loses its insulating myelin sheath. He references Kaneko’s animal experiments where raising NAD levels directly treated the condition, and Hoffer’s clinical results with 3‑6 grams of niacin daily, combined with large doses of other B vitamins, vitamin C, and minerals. Frederick Klenner’s published regimen is explicitly cited as a reproducible treatment. The speaker then introduces the theory of blocked membrane channels caused by heavy metals or thimerosal, preventing nutrient entry into cells. This justifies adding DMSO as a solvent to unblock channels, alongside the vitamin protocol. The stakes: a condition for which patients are told there is no cure can be stabilised or reversed, calling into question the entire pharmaceutical approach.